We identified a novel soluble protein, mouse (m)IL-20R1a, generated by alternative splicing of the mIL-20R1 gene, which encodes one subunit of the receptor complex for mIL-19, mIL-20 and mIL-24. mIL-20R1a has 77.14% amino-acid identity with the extracellular domain of mIL-20R1. However, no significant interaction between mIL-20R1a and mIL-19 or mIL-20 was detected. Consequently, we aimed to clarify whether mIL-20R1a might function as a novel effector on certain cells. Competitive binding assays demonstrated that mIL-20R1a bound to cell surfaces and resulted in AKT and JNK phosphorylation in primary mesangial cells (MCs) isolated from either the wild-type mice, DBA/W mice, or the SLE-prone mice, NZB/W mice. NZB/W MCs expressed more mIL-20R1a transcript than DBA/W MCs did. Furthermore, mIL-20R1a-treated NZB/W MCs produced higher level of chemokines, renal fibrogenic factors and ROS than mIL-20R1a-treated DBA/W MCs did. These factors are involved in the pathogenesis of lupus nephritis. Endogenous mIL-20R1a was upregulated in the bladder, colon and spleen tissue of NZB/ W mice. Elevated mIL-20R1a in the spleen tissue of NZB/W mice was expressed mainly in monocytes and B cells. mIL-20R1a further induced mIL-10 production by the anti-IgM antibody-stimulated B cells in NZB/W mice. Therefore, mIL-20R1a-mediated effects may exacerbate the disease outcome of lupus nephritis.
Introduction
A number of soluble receptors corresponding to the extracellular portions of transmembrane receptors have been identified. 1 These soluble receptors appear to retain their binding characteristics and function as natural antagonists, carrier molecules or biological agonists and sometimes as functional ligands. Consequently, the cellular release of these soluble proteins is tightly regulated, and controlled through different mechanisms.
1,2 Differential mRNA splicing can lead to the secretion of soluble proteins that lack cytoplasmic and membrane-spanning domains of the cognate cell-associated protein. It may also result in reading frame shifts and generating unique COOH-terminal sequences.
Cytokines that signal through class II cytokine receptors (CRF2) form a distinct family that includes the interferons and interleukin-10 (IL-10). Recent identification of several IL-10 homologs has defined a cytokine subfamily that includes IL-19, IL-20, IL-22, IL-24 and IL-26. [3] [4] [5] Within this subfamily, IL-19, IL-20 and IL-24 exhibit substantial sharing of receptor complexes; 6 all three are capable of signaling through IL-20R1/IL-20R2, and both IL-20 and IL-24 can also further use IL-22R1/ IL-20R2. 6 All three receptor subunits belong to the CRF2 family. In response to ligand binding, the CRF2 proteins form heterodimers, leading to cytokine-specific cellular responses. The biological effects of these three cytokines appear quite distinct: immune activity with IL-19, [7] [8] [9] [10] [11] [12] skin biology, atherosclerosis and synovial biology in rheumatoid arthritis with IL-20, [13] [14] [15] [16] [17] [18] [19] [20] and tumor apoptosis with IL-24. [21] [22] [23] [24] [25] [26] Within the CRF2 family, only IL-22 binding protein was identified as a decoy receptor functioning as a naturally occurring, highly specific IL-22 antagonist in both humans [27] [28] [29] and mice. 30 Therefore, we aimed to discover any soluble receptors of IL-20R1. We used RT-PCR to detect the transcript variants of membraneform receptor, mIL-20R1, generated by alternative splicing of mRNA transcripts. We identified one alternative spliced variant of mIL-20R1, termed mIL-20R1a, and explored its biological functions. We performed binding assay, signal transduction assay, gene regulation assay and reactive oxygen species (ROS) production analysis to clarify the effects of mIL-20R1a on specific target cells and its possible association with disease.
Results

Isolation of mIL-20R1 splice variant
Accumulating evidence has revealed the association of IL-19, [8] [9] [10] [11] [12] IL-20 [13] [14] [15] [16] [17] [18] [19] [20] and IL-24 [21] [22] [23] [24] [25] [26] with diseases. To explore if any soluble receptors of these cytokines could function as antagonists of the cytokines, we tried to isolate the alternative spliced transcripts of the receptors for IL-19, IL-20 and IL-24. We performed RT-PCR with primers specific for mIL-20R1 on mouse skin and testis tissues that highly expressed mIL-20R1. 31 An analysis of PCR products showed that mIL-20R1 has two different transcripts in testis tissue. One is identical to what has already been reported (accession number NM_172786.1) and the other is a longer transcript variant that we named 'mIL-20R1a'. An analysis of the nucleotide sequence of the variant revealed two additional exons (exon 2a and exon 3a; exons were numbered based on the structure of the mIL-20R1 gene) ( Figure 1a ). Owing to the insertion of exon 2a in mIL-20R1a, amino-acid residue 105 prematurely terminated the protein, which encoded a soluble form of mIL-20R1 without transmembrane and intracellular domains. Thus, the translated region of the mIL-20R1a gene contains only three exons instead of seven. The nucleotide sequences of mIL-20R1a cDNA were submitted to the GenBank with accession number EF592560.
The amino-acid sequences of mIL-20R1a are 77.14% identical to those of the extracellular domain of mIL-20R1. Hydropathic analysis predicts a hydrophobic signal peptide of 32 amino acids. Beginning with Valine (residue 33), the mature protein containing 73 amino acids has a predicted molecular mass of 11.4 kDa. One potential N-linked glycosylation site was detected in the amino-acid sequences, and the mature protein contains three cysteines (Figure 1b) .
No significant interaction between mIL-20R1a and mIL-19 and mIL-20 As mIL-20R1a was derived from the mIL-20R1 gene, one subunit of the functional receptors of mIL-19 and mIL-20, we performed coimmunoprecipitation studies to explore whether mIL-20R1a bound with these cytokines to regulate their functions. We expressed and purified recombinant proteins of mIL-20R1a, soluble (s)mIL-20R1 and smIL-20R2; the extracellular domains of mIL-20R1 and mIL-20R2, from E. coli. To facilitate expression and purification of these recombinant proteins, they were fused with a fusion protein, maltose-binding protein (MBP). Thus, MBP alone was used as a negative control in the assays. After immunoprecipitating the different protein mixtures, we detected that smIL-20R1 and smIL-20R2 but not MBP recombinant proteins interacted with mIL-19 or mIL-20 using the anti-hIL-19 or anti-hIL-20 antibodies as a co-IP associate ( Figure 2 ). In contrast, mIL-20R1a was not coprecipitated using the anti-hIL-19 or anti-hIL-20 antibodies (Figure 2) . Similarly, we found no significant interaction between immobilized Binding of mIL-20R1a to cell surfaces of mesangial cells mIL-20R1a did not show significant binding with mIL-19 and mIL-20. Therefore, we hypothesized that mIL-20R1a might not function as other soluble receptors to antagonize cytokine activities; instead, it might function as a novel effector. To explore whether mIL-20R1a can bind to cell surface and consequently elicit some effects on the potential target cells, we performed binding assays of mIL-20R1a on several cell lines available in our lab. No obvious binding of mIL-20R1a was observed on U937, RAW264.7, J774A.1, BV-2, BxPC-3, MCF-7, ML-1 4a and H4IIE cell lines (data not shown). However, significant binding of biotinylated mIL-20R1a was observed on two types of mouse mesangial cells (MCs), DBA/W MCs ( Figures 3A and C) and NZB/W MCs ( Figures 3B and C) . DBA/W MCs are MCs isolated from the renal cortex of DB2/A Â NZW mice (DBA/W) with normal phenotypes. NZB/W MCs are MCs derived from New Zealand (NZB Â NZW) F1 mice (NZB/W), which, in aged mice, spontaneously develops a lupus-like syndrome characterized by an increased level of autoantibodies and is an animal model for systemic lupus erythematosus (SLE). Binding of biotinylated mIL-20R1a was gradually diminished in the presence of 1-fold, 5-fold and 10-fold excess of unlabeled mIL-20R1a competitors in the MCs (Figures 3Aa, 3Ba , and 3C). Unlabeled MBP did not show significant competitive effects on mIL-20R1a binding to both MCs (Figures 3Ab,  3Bb, and 3C ). In addition, we found more mIL-20R1a was bound to the cell surface of NZB/W MCs than that of DBA/W MCs ( Figure 3C ). NZB/W MCs expressed higher level of mIL-20R1a transcript than DBA/W MCs did In SLE, the immune system produces antibodies to attack the body's own healthy tissues and organs, including joints, kidneys, heart, lungs, brain, blood or skin. Therefore, binding of mIL-20R1a to these two MCs implies mIL-20R1a may play a role in the progression of lupus nephritis, one of the most serious manifestations of SLE. To investigate the involvement of mIL-20R1a in lupus nephritis, we analyzed and compared the expression of the mIL-20R1a transcript in these two MCs. RT-PCR revealed that the expression level of mIL-20R1a in NZB/ W MCs was much higher than that in DBA/W MCs (Figures 4a and b) .
Signal transduction pathway of mIL-20R1a in MCs
To further study the association of mIL-20R1a with lupus nephritis, we explored whether binding of mIL-20R1a on these two MCs could induce signals and mediate pathological responses in lupus nephritis. Cellular responses of MCs involved in lupus nephritis were shown to be mediated by PI3 kinase/AKT and MAPK signaling, including ERK1/2, p38 MAPK and JNK. 32 To assess whether the activities of these molecules were involved in the mIL-20R1a-mediated responses, we examined the effects of mIL-20R1a and MBP on AKT, ERK1/2, p38 MAPK and JNK phosphorylation in two MCs using western blotting. mIL-20R1a induced AKT and JNK phosphorylation in both MCs after 10 min of treatment (Figures 5a and b) , whereas ERK1/2 phosphorylation was detected only in mIL-20R1a-treated DBA/W MCs (Figure 5a ). The fusion partner of mIL20R1a, MBP, did not induce significant phosphorylation of any molecule in these two MCs (data not shown). ) were incubated with serum-free RPMI-1640 medium for 6 h followed by treatment with serum-free RPMI-1640 medium containing 200 ng ml À1 of mIL20R1a for different time intervals as indicated. Cell lysates were isolated and the levels of phospho-AKT (Ser473), phospho-ERK1/2 (Tyr 204) and phospho-JNK were detected using western blotting with specific antibodies. As an internal control, a-tubulin was used. The experiment was repeated three times with similar results. One representative result of the three is shown. Expression of mIL-20R1a induced by angiotensin II, plateletderived growth factor and lipopolysaccharide Our data provided evidence that the mIL-20R1a-mediated responses in MCs, especially in NZB/W MCs, may be involved in the progression of lupus nephritis. The regulation of mIL-20R1a expression in MCs under the physiological status is still unknown. Angiotensin II, the main effector molecule of the reninangiotensin system, is a strong candidate for the perpetuation of autoimmunity, nephritis and visceral damage in SLE. 35, 36 Platelet-derived growth factor (PDGF) has been implicated in renal injury and more specifically in the activation of MCs. 37 Lipopolysaccharide (LPS) stimulates blood mononuclear cells from SLE patients to release IL-1, which is involved in the immune complex-induced tissue damage in glomerulonephritis. Therefore, we studied whether these SLE-associated factors regulate the expression of mIL-20R1a in wildtype MCs. The expression of mIL-20R1a in DBA/W MCs induced by angiotensin II could be observed after treatment for 4 h and back to the steady-state level after a 6-h treatment. PDGF time-dependently upregulated the transcripts of mIL-20R1a in DBA/W MCs. The level of mIL-20R1a began to rise at the 6h-treatment of PDGF and the levels were maintained higher than the untreated control for 8 h. Similarly, mIL-20R1a was induced in DBA/W MCs upon LPS treatment for 6 h. This upregu- Figure 6 Effect of mIL-20R1a in DBA/W MCs and NZB/W MCs on induction of lupus nephritis-associated factors. RT-PCR was performed as described in Materials and methods. Equal amounts of cDNA and primers specific for CCL-2, CCL-5, CXCL-10 (Aa), TGF-b1, MMP-2 and MMP-9 (Ba) were used in PCR to amplify the transcripts. Primer specific for b-actin was used as an internal control. To prevent overamplification, the transcripts from mIL-20R1a-stimulated NZB/W MCs were amplified for fewer cycles than that from mIL-20R1a-stimulated DBA/W MCs because NZB/W MCs contained more endogenous transcripts than DBA/W MCs did. The relative quantity of PCR products as indicated was shown in bars and expressed as fold of increase relative to untreated controls (Ab and Bb). The experiment was repeated three times with similar results. One representative result of the three is shown. Expression of mIL-20R1a in tissue from DBA/W and NZB/W mice SLE is an autoimmune disease in which the immune system attacks multiple tissues and organs of the body. This disease can affect almost any internal organ in the body (brain, nerves, kidneys, lungs, heart, eyes, gut and bowels), and lead to severe complications. Therefore, we wanted to determine the expression of mIL-20R1a in other SLE-affected organs. Primers specific only for mIL20R1a were used in RT-PCR. Endogenous mIL-20R1a was expressed in brain, colon, kidney, ovary, small intestine, spleen and stomach tissue of DBA/W control mice ( Figure 10 ). In addition, mIL-20R1a was dramatically upregulated in bladder, colon and spleen of NZB/ W mice ( Figure 10 ). mIL-20R1a increased the production of mIL-10 by anti-mIgM antibody-stimulated B cells of NZB/W mice Imbalance in the cytokine network is important for the induction and development of experimental SLE. 38, 39 It was therefore of interest to find out whether the increased mIL-20R1a in splenic B cells of NZB/W mice contributed to the pathogenesis or disease severity of SLE. IL-4, IL-10 and IFN-g are important cytokines involved in the pathogenesis of SLE.
38,39 Therefore, we measured production of these cytokines induced by stimulated B cells that highly expressed mIL-20R1a in 
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NZB/W mice. We treated B cells with mIL-20R1a in the presence of PWM, LPS or anti-mIgM antibody, three frequently used B cell stimulators. mIL-20R1a showed no effect on mIL-10 production by PWM-or LPS-stimulated B cells (data not shown). We did find, however, mIL-10 was upregulated by mIL-20R1a in the B cells of NZB/W mice that had been stimulated with anti-mIgM antibody ( Figure 12 ). Furthermore, splenic cells of NZB/W mice stimulated by anti-mIgM antibody also produced higher level of mIL-10 after mIL-20R1a treatment (data not shown). In contrast, mIL-20R1a treatment had little effect on mIL-10 induction in B cells of DBA/W mice ( Figure 12 ). mIL-20R1a did not induce mIL-4 or mIFNg in stimulated B cells from both types of mice (data not shown).
Discussion
This study identified one novel soluble protein, mIL20R1a, an alternative splicing variant of mIL-20R1. We found binding of mIL-20R1a to MCs isolated from wild-type and SLE mice. Signal transduction was observed following the binding. Further, in vitro assays confirmed the potential role of mIL-20R1a in induction of chemokines and pro-fibrogenic factors and ROS generation in MCs, all of which are associated with the pathogenesis of lupus nephritis. In addition, spleen of mice with SLE expressed higher level of mIL-20R1a when compared with the control mice. The splenic B cells of SLE mice induced mIL-10 production in response to mIL-20R1a treatment. These findings suggested the crucial effect of mIL-20R1a on the modulation of murine lupus. mIL20R1a was generated by adding two extra exons to the original membrane-form receptor, mIL-20R1. The extracellular domain of mIL-20R1 is composed of two fibronectin III domains (D1 and D2) and is critical for ligand binding, particularly for the D1 domain. 5 Only three of seven b-strands in the D1 domain are retained in mIL-20R1a. Furthermore, the entire extracellular domain of IL-20R1 did not inhibit IL-19 or IL-20 activity in competitive luciferase assays. 6 These observations may explain why mIL-20R1a, the truncated form of mIL-20R1, neither significantly binds to mIL-19 and mIL-20 nor modulates these cytokine-induced responses. Therefore, we speculated that mIL-20R1a might not function as a scavenger soluble receptor to antagonize its ligand activity; instead, it might act as a novel effector that mediated certain cellular responses in the tissue. mIL-20R1a had similar effects on ROS generation in MCs of different origin. However, these two primary MCs responded differently to the same treatment of mIL20R1a in signal transduction and the expression of SLErelated modulators such as MMP-2, MMP-9 and TGF-b1. Priming or activation of NZB/W MCs by autoantibodies or other stimuli present in NZB/W mice will result in acquisition of some properties in NZB/W MCs. Therefore, NZB/W MCs become more sensitive in response to mIL-20R1a stimulation.
A significant increase in the binding of mIL-20R1a on NZB/W MCs when compared with that of DAB/W MCs indicated that mIL-20R1a may be a key modulator of, and participant in, the progression of lupus nephritis. The involvement of mIL-20R1a in lupus nephritis was further supported by the increased expression of mIL20R1a in NZB/W MCs when compared with that of DBA/W MCs. These findings suggest that IL-20R1a may act on MCs through an autocrine or a paracrine manner and contribute to the disease development of lupus nephritis.
Binding of mIL-20R1a to both MCs could activate some signaling molecules, including AKT and JNK. All of these signaling molecules mediate some vital effects Figure 11 mIL-20R1a expression in splenocytes from DBA/W and NZB/W mice. Splenic monocytes, B cells and T cells were isolated from DBA/W and NZB/W mice. Total RNA was extracted from these cells after they had been isolated and then underwent reverse transcription with random primers. mIL-20R1a transcript was determined using PCR with specific primers (a). mIL-20R1a expression in conditioned medium (b) of splenocytes from DBA/ W (D) and NZB/W (N) mice 96 h after they had been isolated was detected using western blotting with anti-mIL-20R1 polyclonal antibodies. mIL-20R1a protein with predicted molecular weight is indicated.
Detrimental effects of mIL-20R1a on lupus nephritis C-C Wei and M-S Chang on cell proliferation, migration and differentiation relating to the disease progression of lupus nephritis. 32 The signal transduction findings suggest that these two MCs are potential targets of mIL-20R1a involved in lupus nephritis. Although the specific mechanism through which mIL-20R1a induces cellular signals is still unclear. Identification of mIL-20R1a receptor on MCs will facilitate this investigation. Our knockdown assay using mIL-20R1 shRNA showed that mIL-20R1a-mediated cellular responses were mIL-20R1-independent (data not shown).
Macrophages and other immune cells can release proinflammatory cytokines to promote the growth and activation of MCs. 40, 41 mIL-20R1a may amplify the inflammatory lesion by inducing chemokine production, like CCL-2, CCL-5 and CXCL-10 by MCs. In addition, TGF-b1 is the key element that results in excessive matrix deposition in progressive lupus nephritis. 42 MMP-2 and MMP-9 are involved in the cleavage of TGF-b1 from latent form to active form and their overexpression on glomerular cells plays a critical role in the development of glomerulosclerosis. 43 These three molecules were upregulated by mIL-20R1a only in NZB/W MCs but not in DBA/W MCs. The results further demonstrated the importance of mIL-20R1a in the pathogenesis of lupus nephritis.
Within the IL-10 family, only IL-10 was shown to be involved in the pathogenesis of lupus nephritis. 44, 45 The involvement of other members of the IL-10 family is still unknown. Our unpublished data demonstrated that IL-20 was also associated with lupus nephritis. mIL-20R1a upregulated mIL-20 in two MCs and its receptor subunits in stimulated NZB/W MCs. The data further suggested that mIL-20R1a may also indirectly contribute to the progression of lupus nephritis through mIL-20-mediated responses.
Angiotensin II, PDGF and LPS are known to accelerate the progression of lupus nephritis. 37, 46 Our results showed that these three factors increased the expression of mIL-20R1a in DBA/W MCs. Therefore, angiotensin II, PDGF and LPS may contribute to the development of lupus nephritis not only through their direct effects on renal cells but also through mIL-20R1a-mediated responses.
As bladder, colon, and spleen tissue of SLE mice expressed more mIL-20R1a than that of control mice, whether the increased mIL-20R1a was also involved in the tissue damage of these organs or autoantibody production in SLE may require further studies. Among these SLE-affected organs, the brain expressed the highest level of endogenous mIL-20R1a not only in control mice but also in SLE mice. The physiological role of such abundant mIL-20R1a in the brain awaits further exploration.
Detection of mIL-20R1a protein by anti-mIL-20R1 polyclonal antibody in the conditioned medium of monocytes, B cells and T cells from SLE mice further confirmed that the protein was indeed natively expressed and secreted.
It has been suggested that cytokines are important in the immune dysregulation in lupus-prone mice and in SLE patients. 39, 47 Increased IL-10 production has been reported in all SLE-prone mice, 39 and treatment with IL-10 accelerated disease manifestations, whereas anti-IL-10 delayed the onset of SLE. 48 As endogenous mIL-20R1a was much higher in the spleen tissue of NZB/W mice than in control DBA/W mice, the elevated mIL-20R1a in the monocytes, B cells and T cells of NZB/W mice may accelerate disease manifestations by inducing B cells to produce more IL-10.
We have also isolated several alternatively-spliced variants of human IL-20R1 in various types of tissue (unpublished data). Both HaCaT cells, a human keratinocyte cell line and CaCo2 cells, a human colorectal carcinoma cell line expressed these transcription variants of hIL-20R1. Sequencing analysis of one variant revealed deletion of exon 3 in hIL-20R1 gene, termed hIL-20R1a. Owing to the deletion of exon 3 in hIL-20R1a, amino-acid residue 87 prematurely terminated the protein which encoded a soluble form of hIL-20R1 without transmembrane and intracellular domains. The amino acid sequence of hIL-20R1a protein shares 73% homology with that of mIL-20R1a. The clinical association of these molecules with human lupus nephritis merits further investigation.
To conclude, we isolated and characterized an alternative splicing variant of mIL-20R1, designated mIL20R1a. This soluble protein can act on MCs directly and result in phosphorylation of AKT and JNK. We propose that mIL-20R1a may stimulate the production of chemoattractants by MCs, thus recruiting more inflammatory cells to sustain local inflammation. ROS generation by mIL-20R1a-stimulated MCs will maintain the formation of pathological autoantibodies to hasten the progression of lupus nephritis. In addition, mIL-20R1a may also participate in the development of lupus nephritis to renal fibrosis through overexpression of MMP-2, MMP-9 and TGF-b1. These effects of mIL-20R1a on MCs could be amplified through increased transcription of mIL-20R1a by angiotensin II, PDGF and LPS, important mediators involved in the pathogenesis of lupus nephritis. Furthermore, elevated mIL-20R1a in stimulated splenic B cells produced more IL-10 that may be involved in the progression of SLE. Therefore, mIL-20R1a-mediated effects on MCs and splenic B cells may contribute to the disease outcome of lupus nephritis. This study Figure 12 The effect of mIL-20R1a on mIL-10 production by stimulated B cells of DBA/W and NZB/W mice. B cells from DBA/ W (&) and NZB/W (') mice were stimulated using anti-IgM antibody (10 mg ml
À1
) with or without mIL-20R1a (800 ng ml
) for 96 h. mIL-10 secreted by stimulated B cells was measured using ELISA kits as described in Materials and methods. Figure shown 
Materials and methods
Primary culture of MCs
The primary murine MCs were a gift from Dr Wen-Mein Wu (Fu-Jen Catholic University, Taipei, Taiwan). 49 The culture medium used for all experiments was RPMI-1640 (HyClone, Logan, UT, USA) supplemented with 4 mM L-glutamine, 25 mM HEPES, 2-mercaptoethanol (2.5 Â 10 À5 M), 100 U ml À1 penicillin, 100 mg ml À1 streptomycin and different percentages of fetal bovine serum. The MCs from DBA/2 Â NZW mice (DBA/W MCs) were grown in RPMI-1640 containing 10% fetal bovine serum, and the MCs from NZB Â NZW F1 mice (NZB/W MCs) were grown in RPMI-1640 containing 20% fetal bovine serum. All in vitro experiments were done using primary culture MCs between passages 10 and 20.
Animals
Both female DBA/W and NZB/W F1 mice were obtained from the Animal Center of the College of Medicine of National Taiwan University and were maintained by the Animal Center of our National Defense Medical Center in a specific pathogen-free facility. All procedures were carried out with strict adherence to the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Animal Care and Use Committee of the animal center in National Cheng Kung University, Tainan, Taiwan. , and from Ala 26 to Pro 227 of mIL-20R2 (smIL-20R2) were inserted into pMAL-c2X (New England Biolabs Inc., Beverly, MA, USA), the E. coli expression vector. The recombinant proteins were expressed in E. coli as fusion proteins with maltose-binding protein (MBP) at the N terminus. A six-histidine tag was placed at the C terminus of the recombinant proteins. All fusion proteins were purified using the affinity of MBP for maltose. The purity of the recombinant proteins was evaluated using Coomassie blue staining and western blotting with anti-His antibodies. These proteins were used in coimmunoprecipitation assay and biological function analysis in vitro. MBP by itself was purified and used as a negative control in all in vitro studies.
Coimmunoprecipitation (Co-IP) assays
Co-IP was done as previously described 50 with some minor modifications. Briefly, 400 mM of mIL-19 12 or mIL-20 (R&D systems, MN, USA) recombinant proteins were mixed with equal amounts of mIL-20R1a, smIL-20R1, smIL-20R2 and MBP recombinant proteins. The input proteins were confirmed using western blotting with anti-mIL-19 monoclonal antibodies (R&D Systems), anti-mIL-20 monoclonal antibodies (R&D Systems), anti-mIL-20R1 polyclonal antibodies (R&D Systems), anti-hIL-20R2 polyclonal antibodies (R&D Systems) and anti-MBP polyclonal antibodies (New England Biolabs Inc.). Protein A-agarose pre-cleared supernatants were incubated with anti-hIL-19 polyclonal antibodies 11 or anti-hIL-20 monoclonal antibodies 51 at 4 1C for 1 h, after which protein A-agarose was added and the mixture was incubated at 4 1C for 1 h. Agarose beads were washed two times with cold PBS and eluted into 30 ml of 2 Â SDS-PAGE gel loading buffer by heating at 95 1C for 10 min. The bound proteins were separated using SDS-PAGE and then immunoblotted using anti-mIL-20R1, anti-hIL-20R2 or anti-MBP polyclonal antibodies (New England Biolabs Inc.). Anti-hIL-19, anti-hIL-20 and anti-hIL20R2 antibodies showed cross-species reactivity to recognize both human and mouse proteins.
Surface plasmon resonance
Real time biomolecular interaction analysis was done using a Biacore 3000 instrument (GE Healthcare, Biacore Inc., Piscataway, NJ, USA). All experiments were done at 25 1C using phosphate-buffered saline. In a single experiment, mIL-20R1a recombinant protein together with unfused MBP as a control, were immobilized on a sensor chip through amine-coupling according to the manufacturer's instructions (BIAapplications Handbook; GE Healthcare, Biacore Life Sciences). Typical immobilization levels were between 1000 and 2500 response units. Dilutions of mIL-19 and mIL-20 recombinant proteins were used as the analyte, at a flow-rate of 10 ml min The PCR products were visualized on 2% agarose gels and stained with ethidium bromide. b-actin was an internal control. The relative quantity of the PCR products versus b-actin was analyzed using the Version WorksLS Image Acquisition and Analysis Software (UVP, Upland, CA, USA).
Measurement of ROS production by MCs
MCs (5 Â 10 5 of each type) were incubated at 37 1C with 100 ng ml À1 and 200 ng ml À1 of mIL-20R1a or MBP for 30 min. The ROS activities were determined at the end of the incubation. The CL count was measured in a completely dark chamber of the chemiluminescence analysis system. After a 100-s background level determination, 0.5 ml of 25 mM luminol in PBS (pH 7.4) was injected into the sample. The CL was monitored continuously for an additional 500 s.
Expression of mIL-20R1a in tissue of DBA/W and NZB/W mice Organs from DBA/W and NZB/W female mice more than 6 months old were collected and stored in liquid nitrogen for RNA isolation. Total RNA of tissue was extracted using Trizol (Invitrogen) and then total RNA underwent reverse transcription using SuperScript II (Invitrogen) according to the manufacturer's instructions. mIL-20R1a and b-actin transcripts were amplified using PCR with gene-specific primers.
Isolating monocytes, B cells and T cells from DBA/W and NZB/W female mice Single-cell suspensions depleted of RBCs were prepared from the splenocytes of 3-month-old DBA/W and NZB/ W female mice. Monocytes were allowed to adhere for 30 min at 37 1C in a 5% CO 2 atmosphere. The nonadherent cells were then removed by washing them three times with warm RPMI-1640 medium. T cells were separated from B cells using negative selection with magnetic beads coated with anti-CD19 Ab (Dynal AS, Oslo, Norway) after the monocytes had attached to the plate. B cells were similarly prepared from nonadherent cells, except that the magnetic beads coated with anti-CD3 (Dynal AS) were used for negative selection.
mIL-20R1a expression in conditioned medium of monocytes, B cells and T cells from DBA/W and NZB/W female mice Monocytes, B cells and T cells (2.5 Â 10 7 ml À1 each) from two kinds of mice were harvested 72 h after they had been isolated. Equal amounts of conditioned medium were processed for western blotting analysis using a polyclonal antibody against mIL-20R1 (R&D Systems) according to the manufacturer's instructions.
Cytokine production by splenic B cells from DBA/W and NZB/W female mice Purified B cells (1 Â 10 6 ml
À1
) stimulated by pokeweed mitogen (PWM, 2.5 mg ml À1 ), anti-mouse IgM antibody (10 mg ml À1 ), or LPS (20 mg ml
) were incubated with mIL-20R1a (800 ng ml
). Supernatants were removed after 96 h and analyzed for cytokine content. mIFN-g, mIL-4 and mIL-10 were determined using ELISA kits (R&D Systems) according to the manufacturer's instructions.
Statistical analysis
Values presented are means ± s.d. Significant difference was detected with Student's t-test using a statistical software package in Microsoft Excel. Po0.05 was considered statistically significant.
